TPS in advanced breast cancer during palliative: systemic therapy with special reference to metastatic sites

The Breast ◽  
1993 ◽  
Vol 2 (3) ◽  
pp. 193
Author(s):  
P.I. Jönsson ◽  
M. Malinberg ◽  
G. Nordin
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Special Reference ◽  
Systemic Therapy ◽  
Advanced Breast ◽  
Metastatic Sites

Intensified local treatment and systemic therapy significantly increase time to progression and survival in patients with brain metastases from advanced breast cancer

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 10536-10536
Author(s):  
R. Bartsch ◽  
S. Muschitz ◽  
C. Wenzel ◽  
K. Roessler ◽  
K. Dieckmann ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Brain Metastases ◽  
Advanced Breast Cancer ◽  
Systemic Therapy ◽  
Systemic Treatment ◽  
Local Treatment ◽  
Advanced Breast ◽  
Cytotoxic Agents ◽  
Time To Progression ◽  
Metastatic Sites

10536 Background: Brain metastases (BM) have evolved from a rare to a frequently encountered event in advanced breast cancer (ABC) due to advances in palliative systemic treatment. Especially since the introduction of trastuzumab, different groups reported an increased incidence of BM. In this study, we retrospectively tried to establish factors predicting a prolonged survival in those patients (P). Methods: All P treated at our centre from 1994 to 2004 with whole brain radiotherapy for BM from ABC were included. Cerebral time to progression (cTTP) and overall survival (OS) were calculated using the Kaplan-Meier product limit method. A multivariate analysis (Cox regression) was performed to explore which factors are able to influence significantly cTTP and OS (metastatic sites [visceral versus non-visceral], Karnofsky performance score [KPS], age, intensified local treatment [boost irradiation, neuro-surgical resection], further palliative systemic treatment). Results: Overall 174 P, median age 51 years (y), range 27–76 y, were included. Median cTTP was 3 months (m), range 1–33+ m (95% CI 4.67–7.37). Median OS was 7 m, range 1–44 m (95% CI 5.08– 8.92). Factors significantly influencing cTTP were KPS (p = 0.0024), intensified local treatment (p < 0.0001), and palliative systemic treatment (P = 0.0003). Factors significantly influencing OS were intensified local treatment (p = 0.004), metastatic sites (p = 0.008), KPS (p = 0.006), and palliative systemic treatment (p < 0.001). Conclusion: As shown by the significant influence of metastatic sites, some P die from their advanced systemic disease situation before they would experience cerebral progression, in part explaining the influence of systemic treatment. In other individuals however, intensified local treatment and systemic treatment appear to influence both cTTP and OS significantly, implicating a direct influence of systemic therapy on BM. This might result from an impaired blood brain barrier around metastatic sites, making sufficient tissue concentrations of cytotoxic agents possible. No significant financial relationships to disclose.

scholarly journals Neoadjuvant therapy for breast cancer: updates and proceedings from the Seventh Annual Meeting of the Canadian Consortium for Locally Advanced Breast Cancer

2018 ◽  
Vol 25 (5) ◽  
Author(s):  
A. Arnaout ◽  
J. Lee ◽  
K. Gelmon ◽  
B. Poirier ◽  
F. I. Lu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Systemic Therapy ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Treatment Strategies ◽  
Advanced Breast ◽  
Treatment Modalities ◽  
Neoadjuvant Systemic Therapy ◽  
Academic Debate

Therapy for breast cancer involves a complex interplay of three main treatment modalities: surgery, systemic therapy, and radiation therapy. The Canadian Consortium for Locally Advanced Breast Cancer (LABC) was established with the goal to convene a strong multidisciplinary team of breast oncology clinicians and scientists who are dedicated to the advancement of labc research and treatment, with a vision to drive progress through increased collaboration across disciplines and throughout Canada. The most recent meeting in May 2017 highlighted the latest evidence and literature about the optimal use of neoadjuvant systemic therapy in breast cancer. There is a need for increased clinical and scientific collaboration and the development of guidelines for the use of emerging treatment strategies. The interactive meeting sessions fostered unique opportunities for academic debate and nurtured collaboration between the attendees. 

Nonhormonal Systemic Therapy for Advanced Breast Cancer: Do the Math!

2008 ◽  
Vol 100 (24) ◽  
pp. 1745-1747 ◽  
Author(s):  
Philippe L. Bedard ◽  
Martine J. Piccart-Gebhart
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Systemic Therapy ◽  
Advanced Breast

Inflammatory Component: A Worsening Factor in Locally Advanced Breast Cancer Treated by Radiotherapy and Systemic Therapy

1991 ◽  
Vol 77 (4) ◽  
pp. 331-335 ◽  
Author(s):  
Fernando Guedea ◽  
Albert Biete ◽  
Belen Ojeda ◽  
Carmen Alonso ◽  
Jordi Craven-Bartle
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Systemic Therapy ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Advanced Breast ◽  
Inflammatory Component

scholarly journals Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer – Results from the prospective German TMK cohort study

The Breast ◽  
2017 ◽  
Vol 34 ◽  
pp. 122-130 ◽  
Author(s):  
Thomas Fietz ◽  
Hans Tesch ◽  
Jacqueline Rauh ◽  
Emil Boller ◽  
Lisa Kruggel ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Cohort Study ◽  
Advanced Breast Cancer ◽  
Systemic Therapy ◽  
Advanced Breast

The impact of estrogen receptor (ER), progesterone receptor (PR), and HER-2 receptor status on treatment of patients with advanced breast cancer.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e11580-e11580
Author(s):  
Paramjot Bains ◽  
Erin Diana Powell
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Metastatic Breast ◽  
Advanced Breast ◽  
Her2 Status ◽  
Receptor Status ◽  
Original Tumour ◽  
Number Of Patients ◽  
Metastatic Sites ◽  
The Impact

e11580 Background: There are many variables that affect treatment options and outcomes in advanced breast cancer. The expression of ER, PR and HER2 are key in determining prognosis and management. The traditional management of breast cancer did not involve biopsy of metastatic sites. Recent studies indicate that, in a significant number of patients, there is a change in receptor status in the metastasis, and this may alter treatment. There have been many retrospective studies looking at the change in the ER/PR status of the metastatic site. Change in treatment as a result has been less of a focus. Our objective is to document the likelihood of a change in receptor status and the impact of this on treatment. Methods: This is a single center retrospective chart review. Ethics approval has been obtained through Memorial Univeristy of Newfoundland. The Dr. H. Bliss Murphy Cancer Centre database was used to identify 250 patients in Newfoundland who were diagnosed with metastatic breast cancer between January 2006 and November 2011. The review includes patients diagnosed with de novo metastases and those who developed metastases following adjuvant treatment. The information we are collecting includes ER, PR, and HER2 status of original tumour, whether metastases were biopsied and the results of the biopsy. We are also documenting all treatments administered. Results: The percentage of patients who underwent biopsy of metastases, the likelihood of change in receptor status and the likelihood of change in treatment will be calculated. Approximately half of the charts that met our criteria have been reviewed. Of those 125 patients, 35 had a biopsy specimen analyzed for ER/PR and HER2 status. 6 of these 35 patients had a change in their hormone receptor status, and 3 had a change in their HER2 status. The likelihood of change in treatment recommendations will be determined once all the data have been reviewed. These results will be available for the 2013 ASCO meeting. Conclusions: ER, PR and HER2 status may change from initial diagnosis of breast cancer to metastatic disease. This has important implications for treatment and prognosis, suggesting that biopsy of metastatic sites should be routine.

Sign in / Sign up

Export Citation Format

Share Document